The DESCAR-T registry has been created to meet a request from the French Health Authorities to collect data in order to consolidate the knowledge on the efficacy and safety at both short- and long-term of all CAR T-cell therapies marketed in France.
Treatments by CAR T-cells can cause Cytokine Release Syndrome (CRS) and Immune effector Cell-Associated Neurotoxicity Syndrome (ICANS) adverse effects that can be very severe.
A project, based on the data available in DESCAR-T, will analyse these adverse neurological reactions. The objective is to better describe these events, their occurrence and treatment, and factors that may have an impact on these aspects and on the survival of patients diagnosed with lymphomas.
To the patients that received CAR-T, if you would like more information about the treatment of your data in the DESCAR-T Registry, you can contact the doctor at your centre of care for your CAR-T treatment or make a request at dpo@lysarc.org. You can find more details your rights regarding your data in the section “I am participating or have participated in a clinical trial“, or in the Patient Information Leaflet you received at the time of your inclusion in the registry.